RSV vaccine 90% effective in preventing infant hospitalization

Data from the Centers for Disease Control and Prevention’s New Vaccine Surveillance Network show nirsevimab is 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus.

This finding supports the CDC’s recommendation to protect infants in their first RSV season by giving them nirsevimab if the mother did not receive the maternal RSV vaccine during pregnancy.

RSV is the leading cause of hospitalization among infants in the U.S. The current RSV season is the first time the vaccine was available to protect infants from severe RSV.

Read more: CDC

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.